Krystal Biotech, Inc. $KRYS Shares Newly Bought by Retirement Systems of Alabama

Retirement Systems of Alabama purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 27,476 shares of the company’s stock, valued at approximately $9,137,000. Retirement Systems of Alabama owned about 0.09% of Krystal Biotech as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Hsbc Holdings PLC purchased a new position in shares of Krystal Biotech during the 2nd quarter valued at about $3,653,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Krystal Biotech in the 2nd quarter worth approximately $3,865,000. Allspring Global Investments Holdings LLC boosted its stake in Krystal Biotech by 4.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 54,625 shares of the company’s stock worth $17,770,000 after buying an additional 2,218 shares in the last quarter. Congress Asset Management Co. boosted its stake in Krystal Biotech by 34.8% in the third quarter. Congress Asset Management Co. now owns 54,083 shares of the company’s stock worth $17,986,000 after buying an additional 13,949 shares in the last quarter. Finally, Corient Private Wealth LP boosted its stake in Krystal Biotech by 767.4% in the second quarter. Corient Private Wealth LP now owns 30,558 shares of the company’s stock worth $11,357,000 after buying an additional 27,035 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

KRYS opened at $305.23 on Monday. The company has a market cap of $9.04 billion, a P/E ratio of 41.42 and a beta of 0.56. The business’s 50-day moving average price is $326.76 and its 200-day moving average price is $309.70. Krystal Biotech, Inc. has a 12 month low of $198.02 and a 12 month high of $382.54.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. The company had revenue of $127.34 million during the quarter, compared to analyst estimates of $125.77 million. Equities research analysts forecast that Krystal Biotech, Inc. will post 7.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on KRYS. Bank of America increased their price target on shares of Krystal Biotech from $392.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, September 21st. TD Cowen lowered their price objective on shares of Krystal Biotech from $403.00 to $380.00 and set a “buy” rating for the company in a report on Tuesday, November 3rd. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Wednesday, September 23rd. Zacks Research cut shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a research note on Friday, October 23rd. Finally, Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $375.00.

Get Our Latest Analysis on KRYS

Krystal Biotech Company Profile

(Free Report)

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.

Further Reading

Institutional Ownership by Quarter for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.